AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9886194
Drug: Artesunate (2mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (2mg/kg/day for five days, then 1 mg/kg/day for two days: total=12 mg/kg)
Trial: 9886194
Drug: Artemether (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether (4 mg/kg followed by 2 mg/kg/day for two days, then 1 mg/kg/day for four days: total=12 mg/kg)
Trial: 8002848
Drug: Drug intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug intervention to lower cholesterol levels
Trial: 7698136
Drug: Ramipril (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (titrated from 1.25 mg to a maximum of 10 mg once daily over 4 weeks, mean dose 8 mg)
Trial: 699938
Drug: Intravenous practolol
RxNorm normalized name: practolol
DrugBank: Practolol (DB01297)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous practolol 15 mg followed by oral practolol 200 mg at 12 h intervals
Trial: 699938
Drug: Intravenous practolol
RxNorm normalized name: practolol
DrugBank: Practolol (DB01297)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous practolol
Trial: 22436475
Drug: Intra-articular lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular lidocaine (IAL) - 4 mg/kg (up to 200 mg) of 1% lidocaine injected into the glenohumeral joint.
Trial: 22436475
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation (IVS) - medications for sedation as per physician discretion.
Trial: 19018157
Drug: D-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS) 50 mg weekly
Trial: 11842271
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate supplementation (5-day load of 0.3 g/kg(-1) x day(-1) followed by a 5-week maintenance dose of 0.03 g/kg(-1) x day(-1))
Trial: 11842271
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate supplementation (5-week maintenance dose)
Trial: 9788454
Drug: Ramipril (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (1.25 to 5.00 mg/day)
Trial: 9788454
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus conventional antihypertensive therapy
Trial: 2969551
Drug: Heparin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin therapy combined with anti-thrombosis stockings
Trial: 31226238
Drug: Bioabsorbable implant
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioabsorbable implant (Latera)
Trial: 25029005
Drug: Caffeine 5
RxNorm normalized name: caffeine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 5 mg.kg of body mass
Trial: 25029005
Drug: Caffeine 10
RxNorm normalized name: caffeine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 10 mg.kg of body mass
Trial: 25029005
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg.kg of body mass)
Trial: 15237655
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin (300 ml per day for 72 hours)
Trial: 15237655
Drug: HES 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 500 ml (per day for 72 hours)
Trial: 15237655
Drug: HES 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 1000 ml (per day for 72 hours)
Trial: 15237655
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (1000 ml per day for 72 hours)
Trial: 11236257
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (40 patients with stabilized UA after pharmacological treatment)
Trial: 8800298
Drug: Calcipotriol ointment
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol ointment (50, 10, 2, 0.4 micrograms/g)
Trial: 1735081
Drug: 5-fluorouracil (5-FU,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (5-FU, 700 mg/m2/d), folinic acid (FA, 300 mg/m2/d), and oxaliplatin (l-OHP, 25 mg/m2/d) infused continuously for 5 days every 3 weeks, modulated sinusoidally over 24 hours.
Trial: 1735081
Drug: Infusion rate
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate modulated according to circadian rhythms.
Trial: 1735081
Drug: 5-fluorouracil (5-FU,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (5-FU, 700 mg/m2/d), folinic acid (FA, 300 mg/m2/d), and oxaliplatin (l-OHP, 25 mg/m2/d) infused continuously for 5 days every 3 weeks.
Trial: 3883700
Drug: Antacid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid treatment (10 ml of an antacid suspension seven times a day, buffering 367.5 mmol acid)
Trial: 28739263
Drug: Subcutaneous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous ketamine (0.1, 0.2, 0.3, 0.4, and 0.5 mg/kg)
Trial: 28739263
Drug: Repeated treatments
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated treatments of subcutaneous ketamine
Trial: 16866794
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 25 microg every 3 h (group 1, n = 100)
Trial: 16866794
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol followed by oxytocin (group 2, n = 100)
Trial: 16866794
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (group 1)
Trial: 14678208
Drug: 4.0 mg
RxNorm normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mg nickel sulfate hexahydrate
Trial: 14678208
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg nickel sulfate hexahydrate
Trial: 14678208
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg nickel sulfate hexahydrate
Trial: 10520053
Drug: Birch pollen
RxNorm normalized name: Gray birch pollen
DrugBank: Betula populifolia pollen (DB10724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birch pollen allergoid immunotherapy (IT) plus symptomatic treatment
Trial: 1822906
Drug: Praziquantel 50
RxNorm normalized name: praziquantel 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 50 mg/kg/day for 15 days
Trial: 1822906
Drug: Albendazole 15
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 15 mg/kg/day for 30 days
Trial: 6456140
Drug: Topical erythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical erythromycin base 2%
Trial: 26971543
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (ET)
Trial: 23519054
Drug: Herbal mucoadhesive
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Herbal mucoadhesive tablets
Trial: 23519054
Drug: Placebo mucoadhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mucoadhesive tablets
Trial: 21184622
Drug: Nilotinib 800
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 800 mg
Trial: 21184622
Drug: Warfarin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 25 mg alone (placebo control)
Trial: 18808378
Drug: Topical betulin-based
RxNorm normalized name: betulin
DrugBank: Betulin (DB16890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betulin-based oleogel twice daily
Trial: 18808378
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cryotherapy with topical betulin-based oleogel
Trial: 9702934
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg titrated to losartan 50 mg/hydrochlorothiazide (HCT) 12.5 mg
Trial: 9702934
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg titrated to 10 mg
Trial: 30650444
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of ADP to agonist in obese patients and SERCA3-inhibited control platelets
Trial: 21073363
Drug: Eplerenone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (up to 50 mg daily)
Trial: 18341017
Drug: ROM (rifampicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROM (rifampicin, ofloxacin, and minocycline) administered by body weight to adults above 15 years; RMP (rifampicin) administered by body weight to children below 15 years.
Trial: 18341017
Drug: Vitamins administered
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins administered to non-treated group.
Trial: 16818928
Drug: Cysticidal drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysticidal drug therapy
Trial: 14505199
Drug: Transmeatal cochlear
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmeatal cochlear laser treatment (TCL) using diode lasers (lambda=635 nm, 7.8 mW cw, n=17 and lambda=830 nm, 20 mW cw, n=18) with a space irradiation of 4 J/cm2 at the site of maximal cochlear injury.
Trial: 14505199
Drug: Transmeatal cochlear
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmeatal cochlear laser treatment (TCL)
Trial: 6864076
Drug: Iron therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron therapy for 2 weeks
Trial: 17585028
Drug: Total urinary
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total urinary excretion
Trial: 12214463
Drug: TAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP therapy (TXL 160 mg/m2 3 h, day 2, ADM 45 mg/m2, day 1, CDDP 50 mg/m2 day 1)
Trial: 12214463
Drug: AP therapy
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP therapy (ADM 60 mg/m2, CDDP 50 mg/m2)
Trial: 12078199
Drug: 3 tablets
RxNorm normalized name: Xpovio 60 MG Weekly Dose Carton Pack, 4 Blister Cards, 3 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets of albendazole composite
Trial: 12078199
Drug: 2 tablets
RxNorm normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of albendazole composite
Trial: 12078199
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 400 mg of albendazole
Trial: 12078199
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 10 mg base/kg of pyrantel pamoate
Trial: 12078199
Drug: 1.5 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 tablets of albendazole composite
Trial: 12078199
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of pyrantel pamoate
Trial: 2686955
Drug: Cefotetan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (2 g) administered as i.v. bolus 30 min before operation
Trial: 2686955
Drug: Piperacillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (2 g) administered as i.v. bolus 30 min before operation
Trial: 28363687
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment strategy with angiographic guidance (n=450)
Trial: 28363687
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment strategy with angiographic guidance (n=449)
Trial: 28363687
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment strategy
Trial: 26131189
Drug: LJCT (Lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LJCT (Lower Joint Cavity Treatment)
Trial: 26131189
Drug: UJCT (Upper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UJCT (Upper Joint Cavity Treatment)
Trial: 16467019
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg daily for at least 60 days
Trial: 16467019
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (only emollients for topical therapy)
Trial: 11288031
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (50 mU/kg/h) for 4 hours
Trial: 8461565
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride (NaF) administered continuously
Trial: 8461565
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride (NaF) administered cyclically
Trial: 8461565
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride (NaF) administered cyclically (50-60 mg/day)
Trial: 3488178
Drug: Fibrin sealing
RxNorm normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin sealing for treatment of manifest lymph fistulae (n = 9)
Trial: 27524190
Drug: CEE+ MPA
RxNorm normalized name: polyurethane-34 (55 MPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE+ MPA sequential therapy
Trial: 27524190
Drug: E2V+ MPA
RxNorm normalized name: MPA
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2V+ MPA sequential therapy
Trial: 27524190
Drug: E2V+ P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2V+ P sequential therapy
Trial: 18580019
Drug: Antibiotic-lock therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-lock therapy using vancomycin and gentamycin
Trial: 16197624
Drug: Irinotecan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 200 mg/m2 on day 1, levo-leucovorin (LV) 250 mg/m2, and 5-fluorouracil (5-FU) 850 mg/m2 via intravenous bolus on day 2
Trial: 879070
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing cystine at 6 mg/100 ml
Trial: 879070
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing cystine at 28 mg/100 ml
Trial: 879070
Drug: Dietary intake
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intake of tyrosine less than 50 mg/kg of body weight
Trial: 23542637
Drug: valacyclovir 1000
RxNorm normalized name: valacyclovir 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valacyclovir 1000 mg twice daily
Trial: 23542637
Drug: acyclovir 400
RxNorm normalized name: acyclovir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acyclovir 400 mg twice daily
Trial: 21884720
Drug: Carisoprodol 700
RxNorm normalized name: Carisoprodol
DrugBank: Carisoprodol (DB00395)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carisoprodol 700 mg
Trial: 19908948
Drug: Carisoprodol 350
RxNorm normalized name: carisoprodol 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carisoprodol 350 mg
Trial: 21884720
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg carisoprodol)
Trial: 14659122
Drug: Mastectomy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mastectomy or breast conservation with or without radiation therapy
Trial: 1412641
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg/kg body weight) + Desipramine (1.3-2.8 mg/kg body weight) daily for 3 days
Trial: 3874641
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 mg kg‐1
Trial: 3874641
Drug: Etomidate 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 0.2 mg kg‐1
Trial: 3874641
Drug: Methohexitone 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexitone 1.5 mg kg‐1
Trial: 28502186
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with VP, indomethacin, and treatment of bacterial vaginosis (BV)
Trial: 28502186
Drug: Dydrogesterone, 17-OH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone, 17-OH progesterone (17OHP), and micronized oral progesterone (OP)
Trial: 26242382
Drug: JNJ‐54452840 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐54452840 20 mg
Trial: 26242382
Drug: JNJ‐54452840 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐54452840 80 mg
Trial: 26242382
Drug: JNJ‐54452840 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐54452840 240 mg
Trial: 22686076
Drug: Xinganbao Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinganbao Capsule (8 capsules, three times a day)
Trial: 22686076
Drug: Heluo Shugan
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heluo Shugan Tablet (5 pills, thrice daily)
Trial: 16580386
Drug: Simvastatin, 20
RxNorm normalized name: Simvastatin, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, 20 mg daily plus oral contraceptive pill (OCP)
Trial: 27488933
Drug: Ramosetron 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.6 mg
Trial: 10648342
Drug: Ramosetron 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.15 mg
Trial: 14749148
Drug: Ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.3 mg vs Ramosetron 0.6 mg
Trial: 6778197
Drug: Diltiazem 120
RxNorm normalized name: diltiazem 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 120 mg/day
Trial: 31143922
Drug: Cervical headgear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical headgear worn for 12 hours daily
Trial: 29540069
Drug: Carbon monoxide
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon monoxide inhalation (carboxyhemoglobin 22%)
Trial: 12675644
Drug: Intensified management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified management with diet, exercise, and insulin
Trial: 10872954
Drug: Continuous non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous non-surgical therapy (one or more non-surgical procedures performed during 3 successive years)
Trial: 10872954
Drug: Intermittent non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent non-surgical therapy
Trial: 2008547
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine system (TNS)
Trial: 1844692
Drug: Treatment effects
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effects across centers
Trial: 31850484
Drug: Combined mouthwash
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined mouthwash formulation containing natural antibiofilm agents
Trial: 31850484
Drug: Combined mouthwash
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined mouthwash formulation
Trial: 28656510
Drug: Alprostadil hydration
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil hydration (10 μg/day for 3 days plus 20 ml normal saline)
Trial: 28656510
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (20 ml normal saline for 3 days)
Trial: 3532009
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg three times a day for 4 weeks)
Trial: 26636489
Drug: Fibrin sealant
RxNorm normalized name: FIBRIN SEALANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin sealant patch
Trial: 29715355
Drug: Insulin (n=454)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin (n=454)
Trial: 28049818
Drug: Short-chain galactooligosaccharide
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-chain galactooligosaccharide (GOS) treatment, designated 'RP-G28', administered over 36 days.